Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 7:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 312 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 3TC Clear all

Conditions: HIV Infections
Interventions: Indinavir sulfate, Nelfinavir mesylate, Lamivudine, Stavudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Chronic HBV Infection
Interventions: GS-4774, OAV Regimen; Biological · Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 16
States / cities: Los Angeles, California • Pasadena, California • Sacramento, California + 13 more

Conditions: HIV Infections
Interventions: Ritonavir, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Saquinavir, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 5
States / cities: Chicago, Illinois • Baltimore, Maryland • New York, New York

Conditions: HIV Infections
Interventions: Efavirenz, Lamivudine, Stavudine; Drug
Lead sponsor: Dupont Merck; Industry
Eligibility: 13 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Brookline, Massachusetts • Columbus, Ohio + 4 more

Conditions: HIV Infections, Pregnancy
Interventions: Lamivudine, Lamivudine/Zidovudine, Nelfinavir mesylate, Nevirapine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 14 Years and older · Female only
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 44
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 28 more

Conditions: HIV Infections
Interventions: Placebo tablets; Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: HIV Infections
Interventions: Ritonavir, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Month to 2 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 12
States / cities: Long Beach, California • San Diego, California • Washington D.C., District of Columbia + 5 more

Conditions: Chronic Hepatitis B
Interventions: ACH126, 433; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 13
States / cities: Los Angeles, California • Orange, California • Pasadena, California + 8 more

Conditions: HIV-1 Infection
Interventions: Teropavimab, Zinlirvimab, Lenacapavir Tablet, Lenacapavir Injection, Antiretroviral Therapy; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 29
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 25 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: ABC/DTG/3TC FDC tablet; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Glendale, California

Conditions: HIV Infections
Interventions: Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Lamivudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 8
States / cities: San Francisco, California • Washington D.C., District of Columbia • Altamonte Springs, Florida + 5 more

Conditions: HIV Infections
Interventions: Saquinavir, Lamivudine, Zidovudine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: San Francisco, California • Sherman Oaks, California • New York, New York

Conditions: HIV Infections
Interventions: Lamivudine, Zidovudine, Zalcitabine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 18
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 14 more

Conditions: HIV Infections
Interventions: Lopinavir/Ritonavir, Nelfinavir mesylate, Lamivudine, Stavudine; Drug
Lead sponsor: Abbott; Industry
Eligibility: 12 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 42
States / cities: Beverly Hills, California • Fountain Valley, California • Los Angeles, California + 31 more

Conditions: HIV Infections
Interventions: Raltegravir and Abacavir/Lamivudine; Drug
Lead sponsor: Denver Infectious Disease Consultants, PLLC; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Phoenix, Arizona • Denver, Colorado • Santa Fe, New Mexico

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine, Capravirine, Nelfinavir mesylate; Drug
Lead sponsor: Agouron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 46
States / cities: Tucson, Arizona • Los Angeles, California • Oakland, California + 39 more

Conditions: HIV Infections, Human Immunodeficiency Virus
Interventions: Dexelvucitabine; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 10
States / cities: Long Beach, California • Brandon, Florida • Fort Lauderdale, Florida + 7 more

Conditions: HIV
Interventions: fos-amprenavir calcium, ritonavir, abacavir/lamivudine as Epzicom; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV Infections
Interventions: Abacavir sulfate, Nelfinavir mesylate, Lamivudine, GW433908; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 23
States / cities: Concord, California • Long Beach, California • Orlando, Florida + 15 more

Conditions: Chronic Hepatitis B
Interventions: Entecavir + Tenofovir, Adefovir + continuing Lamivudine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 1 more

Conditions: HIV Infections
Interventions: Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions: abacavir/lamivudine, abacavir, lamivudine, tenofovir; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 30
States / cities: Los Angeles, California • Oakland, California • Fort Lauderdale, Florida + 20 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Ritonavir, Lamivudine, Stavudine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 18
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 9 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Effectiveness of Anti-HIV Drugs in Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages of HIV Infection

Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B

The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs

A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy

B/F/TAF Ease of Swallowability Trial

A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children

Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects

A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir

A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients

The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT

A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy

Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects

Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients

Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs

A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination

Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy

A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection

To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily

The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients